PCSA | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 24%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.50%

1 Month

1,349.22%

3 Months

1,718.65%

6 Months

1,236.12%

1 Year

266.77%

2 Year

681.04%

Key data

Stock price

$3.51

P/E Ratio

0.00

DAY RANGE

$3.32 - $3.70

EPS

-$1.51

52 WEEK RANGE

$0.11 - $8.88

52 WEEK CHANGE

$266.77

MARKET CAP

9.662 M

YIELD

N/A

SHARES OUTSTANDING

56.644 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

2.05

PUBLIC FLOAT

AVERAGE 10 VOLUME

$8,151,866

AVERAGE 30 VOLUME

$3,662,154

Company detail

CEO: David Young
Region: US
Website: processapharmaceuticals.com
Employees: 20
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Processa Pharmaceuticals, Inc. focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the. treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company was incorporated in 2011 and is based in Hanover, Maryland.

PCSA - Processa Pharmaceuticals, Inc.